Evidence map›Paper›PMID 37433230›Full record

ArticleClinical nutrition (Edinburgh, Scotland)2023

Ketogenic diet in relapsing multiple sclerosis: Patient perceptions, post-trial diet adherence & outcomes.

Emma Wetmore, Diana Lehner-Gulotta, Brian Florenzo, Brenda Banwell, A G Christina Bergqvist, Rachael Coleman, Mark Conaway, Myla D Goldman, J Nicholas Brenton

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Clinical nutrition (Edinburgh, Scotland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03718247 (The Effect of the Ketogenic Diet on Patients With Relapsing Remitting Multiple Sclerosis), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03718247 completednot on this map

The Effect of the Ketogenic Diet on Patients With Relapsing Remitting Multiple Sclerosis

TypeobservationalSponsorUniversity of VirginiaRan2018 to 2021Enrolled45ConditionsRelapsing Remitting Multiple SclerosisArmsModified Atkins diet
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Emma WetmoreDept of Neurology, University of Virginia, Charlottesville, VA, USA; School of Medicine, Medical University of South Carolina, Charleston, SC, USA.
Diana Lehner-GulottaDept of Neurology, University of Virginia, Charlottesville, VA, USA; Division of Child Neurology, Dept. of Neurology, University of Virginia, Charlottesville, VA, USA.
Brian FlorenzoSchool of Medicine, University of Virginia, Charlottesville, VA, USA.
Brenda BanwellDivision of Child Neurology, Children's Hospital of Philadelphia, Dept. of Neurology and Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
A G Christina BergqvistDivision of Child Neurology, Children's Hospital of Philadelphia, Dept. of Neurology and Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Rachael ColemanDept of Neurology, University of Virginia, Charlottesville, VA, USA.
Mark ConawayDept of Public Health Sciences, University of Virginia, Charlottesville, VA, USA.
Myla D GoldmanDept of Neurology, Virginia Commonwealth University, Richmond, VA, USA.
J Nicholas BrentonDept of Neurology, University of Virginia, Charlottesville, VA, USA; Division of Child Neurology, Dept. of Neurology, University of Virginia, Charlottesville, VA, USA. Electronic address: jnb8h@uvahealth.org.
University of Virginia · USChildren's Hospital of Philadelphia · USMedical University of South Carolina · USVirginia Commonwealth University · US

Funding

The integrated Translational Health Research Institute of Virginia (iTHRIV): Using Data to Improve HealthUL1TR003015 · NCATS · UNIVERSITY OF VIRGINIA · PI BROWN, DONALD E, JOHNSTON, KAREN C. · 2019 to 2023
$20.3M
Institutional Career Development CoreKL2TR003016 · NCATS · UNIVERSITY OF VIRGINIA · PI PAPIN, JASON, WORRALL, BRADFORD B · 2019 to 2023
$3.9M
Obesity as a Driver of Inflammation and Brain Volume Loss in Pediatric Multiple SclerosisK23NS116225 · NINDS · UNIVERSITY OF VIRGINIA · PI BRENTON, JAMES NICHOLAS · 2021 to 2025
$962k
NCATS NIH HHS KL2 TR003016NCATS NIH HHS UL1 TR003015NINDS NIH HHS K23 NS116225
6 · The paper itself

Abstract

backgroundKetogenic diets (KDs) are safe and tolerable in people with multiple sclerosis (MS). While many patient-reported and clinical benefits are noted, the sustainability of these diets outside of a clinical trial is unknown.

aimsEvaluate patient perceptions of the KD following intervention, determine the degree of adherence to KDs post-trial, and examine what factors increase the likelihood of KD continuation following the structured diet intervention trial.

methodsSixty-five subjects with relapsing MS previously enrolled into a 6-month prospective, intention-to-treat KD intervention. Following the 6-month trial, subjects were asked to return for a 3-month post-study follow-up, at which time patient reported outcomes, dietary recall, clinical outcome measures, and laboratory values were repeated. In addition, subjects completed a survey to evaluate sustained and attenuated benefits following completion of the intervention phase of the trial.

resultsFifty-two subjects (81%) returned for the 3-month post-KD intervention visit. Twenty-one percent reported continued adherence to a strict KD and an additional 37% reported adhering to a liberalized, less restrictive form of the KD. Those subjects with greater reductions in body mass index (BMI) and fatigue at 6-months on-diet were more likely to continue on KD following trial completion. Using intention-to-treat analysis, patient-reported and clinical outcomes at 3-months post-trial remained significantly improved from baseline (pre-KD), though the degree of improvement was slightly attenuated relative to outcomes at 6-months on KD. Regardless of diet type following the KD intervention, dietary patterns shifted toward greater protein and polyunsaturated fats and less carbohydrate/added sugar consumption.

conclusionsFollowing the 6-month KD intervention study, the majority of subjects elected to continue on KD, though many pursued a more liberal limit for carbohydrate restriction. Those who experienced a greater reduction in BMI or fatigue were more likely to continue with strict KD. The 6-month KD intervention induced persistent changes to dietary habits in the months following study completion. TRIAL REGISTRATION INFORMATION: Registered on Clinicaltrials.gov under registration number NCT03718247, posted on Oct 24, 2018. First patient enrollment date: Nov 1, 2018. Link: https://clinicaltrials.gov/ct2/show/NCT03718247?term=NCT03718247&draw=2&rank=1.

Indexed as

Diet, KetogenicMultiple SclerosisCarbohydratesFatigueHumansProspective StudiesCarbohydratesAutoimmuneDietaryModified atkinsNeuroimmunologyObesity

Identifiers

PMID37433230
PMCPMC10528668
OpenAlexW4382930382

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.